One of the biggest commercial challenges that biotechnology firms faced in the 1980s has only just been resolved: Glycofi has come up with a way to manufacture human therapeutic proteins in yeast and other fungal protein expression systems. The firm figures the first adopters will be companies that have identified proteins they know are pharmacologically active, but which cannot be produced in sufficient quantity with now-standard mammalian cell culture techniques.
21 Lafayette Street, Canterra Park
Lebanon, NH 03766
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
